Tyra Biosciences announced initial results from a Phase 2 trial of its cancer drug dabogratinib, revealing significant Grade 3 adverse events in patients. Following this, the company's stock fell nearly 18%. Pomerantz LLP is investigating whether Tyra and its executives engaged in securities fraud or unlawful practices related to the trial data disclosure. Investors affected by the stock drop are advised to contact the law firm for potential class action participation.
Tyra Biosciences is the subject of an investor investigation following adverse trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 19:42 WIB: 74 of 91 health-sector stocks rose today. Notable movers include Twist Bioscience Corp at USD 148.47 with a 3.77% increase, AbCellera Biologics Inc at USD 12.07 up 3.43%, and Ascendis Pharma A/S at USD 239.50 down 3.31%.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
